V.A. Gritsyuk

V.A. Gritsyuk

Auto-generated profile, based on publicly available information

V.A. Gritsyuk

Всероссийский государственный центр качества и стандартизации лекарственных средств для животных и кормов

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Transactions of the educational establishment “Vitebsk the Order of “the Badge of Honor” State Academy of Veterinary Medicine
Verified
Journal Article
Closed access
VGV.A. Gritsyuk
V.A. Gritsyuk
GVG.A. Vostroilova
G.A. Vostroilova
NKN.T. Klimov
N.T. Klimov
NKN.A. Khokhlova
N.A. Khokhlova
VZV.I. Zimnikov
V.I. Zimnikov
AKA.A. Korchagina
A.A. Korchagina
The objective of this study was to determine the therapeutic efficacy of the drug "Submastin-Cattle" in the treatment of subclinical mastitis in cattle. The trials were carried out on cows with subclinical mastitis on the farms of the Voronezh region. The animals were divided into two groups on the principle of analogies. The cows of the first group were treated with "Submastin-Cattle" twice at a dose of 10 ml with an interval of 24 hours. The animals of the second group (control) received placenta denatured emulsified (PDE) as required by the product direction. It has been found that the use of the drug "Submastin-Cattle" allows to achieve 83.6% of therapeutic efficacy, which is by 16.0% higher than when using PDE.

31 March 2025 in BULLETIN OF VETERINARY PHARMACOLOGY
Verified
Journal Article
Closed access
ГВГ.а. Востроилова
Г.а. Востроилова
ВГВ.а. Грицюк
В.а. Грицюк
ЛЧЛ.в. Ческидова
Л.в. Ческидова
ВЗВ.и. Зимников
В.и. Зимников
АКА.а. Корчагина
А.а. Корчагина
В статье представлены результаты изучения эффективности схемы лечения мастита у коров, включающей применение комплексного препарата «Диомаст-КРС» и Липотона. Для проведения экспериментальных исследований было отобрано 49 коров, больных маститом, которые по принципу аналогов были распределены в 2 группы. Животным первой группы применяли Диомаст-КРС согласно инструкции, второй группе дополнительно внутримышечно вводили Липотон в дозе 0,02 мл/кг двукратно с интервалом 48 часов. Установлено, что наилучший терапевтический эффект получен при совместном применении Липотона и Диомаста-КРС, который при гнойно-катаральной форме мастита составил 92,3 %, при катаральной — 91,7 %, что выше показателей базового варианта на 7,7—9,9 %, при этом излечено 93,3 и 92,3 % долей вымени соответственно. Контаминация молока микрофлорой снизилась при введении Диомаста-КРС в 4 раза, а при дополнительном использовании Липотона — в 6 раз и при этом бактерионосительство было ниже в 1,5 раза. Терапия больных маститом коров при применении Липотона сопровождалась более ранним купированием воспалительного процесса в молочной железе, выраженной активизацией гуморального и клеточного звена естественной резистентности, интенсивным снижением процессов пероксидации липидов и активизацией ферментативного и неферментативного звена антиоксидантной защиты. The article presents the results of studying the efficacy of the therapeutic regimen for bovine mastitis, including the use of the complex drug “Diomast-KRS” and Lipoton. For experimental studies, 49 cows with mastitis were selected, which were divided into 2 groups according to the principle of analogues. The animals of the first group were given “Diomast-KRS” according to the instructions, the second group was additionally administered Lipoton intramuscularly at a dose of 0.02 ml/kg twice with an interval of 48 hours. It had been found that the best therapeutic effect was obtained with the combined use of Lipoton and “Diomast-KRS”, which was 92.3 % for purulent-catarrhal mastitis, 91.7 % — for catarrhal mastitis, which was by 7.7—9.9 % higher than the baseline values, while 93.3 and 92.3 % of the udder lobes were cured, respectively. Milk contamination with microflora decreased by 4 times with the introduction of “Diomast-KRS”, and by 6 times with the additional use of Lipoton, while the bacterial carriage was by 1.5 times lower. Therapy of cows with mastitis using Lipoton was accompanied by earlier relief of the inflammatory process in the mammary gland, pronounced activation of the humoral and cellular links of natural resistance, an intensive decrease in lipid peroxidation processes and activation of the enzymatic and non-enzymatic links of antioxidant protection.

1 January 2023 in Transactions of the educational establishment “Vitebsk the Order of “the Badge of Honor” State Academy of Veterinary Medicine
Verified
Journal Article
Closed access
VGV.A. Gritsuk
V.A. Gritsuk
PPP.A. Parshin
P.A. Parshin
GVG.A. Vostroilova
G.A. Vostroilova
ISI.T. Shaposhnikov
I.T. Shaposhnikov
AKA.A. Korchagina
A.A. Korchagina
DSD.I. Shabanov
D.I. Shabanov

1 January 2023 in Transactions of the educational establishment “Vitebsk the Order of “the Badge of Honor” State Academy of Veterinary Medicine
Verified
Journal Article
Closed access
VGV.A. Gritsyuk
V.A. Gritsyuk
GVG.A. Vostroilova
G.A. Vostroilova
AKA.A. Korchagina
A.A. Korchagina
NKN.A. Khokhlova
N.A. Khokhlova
DSD.I. Shabanov
D.I. Shabanov
ANA.V. Nekrasov
A.V. Nekrasov

1 January 2022 in Transactions of the educational establishment “Vitebsk the Order of “the Badge of Honor” State Academy of Veterinary Medicine
Verified
Journal Article
Closed access
GVG.A. Vostroilova
G.A. Vostroilova
VGV.A. Gritsyuk
V.A. Gritsyuk
DSD.I. Shabanov
D.I. Shabanov
AKA.A. Korchagina
A.A. Korchagina
NKN.A. Khokhlova
N.A. Khokhlova
In this research, we studied the potential mutagenic and toxic effects of the drug Submastin-KRS, which contains a mixture of species-specific bovine recombinant cytokines and vitamin A as active ingredients, on the body of white laboratory outbred mice (n=48). The animals were divided into 8 groups, 6 individuals in each one. A single injection of Submastin-KRS at a therapeutic and high dose (1/10 of LD50) did not lead to a statistically significant increase in the frequency of polymorphonuclear erythrocytes (PCE) with micronuclei and a decrease in the proportion of PCE in the bone marrow of the mice. The combined administration of Submastin-KRS and experimental mutagens (dioxidin, mitomycin C) it also caused neither potentiation of mutagenic activity nor a decrease in the frequency of PCE with micronuclei. Fourfold administration of Submastin-KRS at a high dose with an interval of 24 hours before the injection of mitomycin C had an antitoxic effect that was expressed in a statistically significant increase in the proportion of PCE in the bone marrow, relative to mice that received only mitomycin C. A similar administration of dioxidine together with Submastin-KRS did not lead to differences in the proportion of PCE relative to this indicator with the introduction of dioxidine alone. Thus, Submastin-KRS showed no mutagenic and toxic properties in relation to mouse bone marrow cells and also had an antitoxic effect in mitomycin-induced suppression of hematopoiesis that may serve as the evidence of its safety.

1 January 2022 in Transactions of the educational establishment “Vitebsk the Order of “the Badge of Honor” State Academy of Veterinary Medicine
Verified
Journal Article
Closed access
GVG.A. Vostroilova
G.A. Vostroilova
VGV.A. Gritsyuk
V.A. Gritsyuk
DSD.I. Shabanov
D.I. Shabanov
AKA.A. Korchagina
A.A. Korchagina
OGO.A. Golodnova
O.A. Golodnova
The article presents the results of studying mutagenic activity of the two-component drug Diomast-KRS (compo-nent 1 - recombinant bovine cytokines and vitamin A, component 2 - dioxidine and vitamin A), and its components separately with a single injection by means of a micronucleus test. White laboratory mice (n=36) were selected for the experiment. They were divided into 6 groups, 6 individuals in each one. It has been found that a single use of the drug Diomast-KRS at therapeutic and high doses (1/10 of LD50) does not cause statistically significant deviations in the number of micronuclei and the percentage of polychromatophilic erythrocytes in the bone marrow of white laboratory mice relative to the control values. The components of the drug used separately also did not cause changes in cytogenetic stability in the bone marrow cells of mice. Thus, the drug Diomast-KRS does not have a pronounced mutagenic effect at the tested doses.